Coronavirus Vaccine - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510243181

Publication Date:

October 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Coronavirus vaccines refer to biological products made from coronaviruses for vaccination. It mainly includes inactivated coronavirus vaccine, live attenuated coronavirus vaccine, coronavirus vaccine based on S protein and so on.
The global market for Coronavirus Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Coronavirus Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Coronavirus Vaccine by region & country, by Type, and by Application.
The Coronavirus Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Coronavirus Vaccine.
麻豆原创 Segmentation
By Company
袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧
袦芯诲械谤苍邪
狈芯惫邪惫邪褏
袪r芯t械褨n 袪芯t械nt褨邪l
袗濒褉丑邪痴邪褏
袇褍n邪褨rg械n 袪L小
狈邪苍芯痴褨谤褨褋褨诲械褧
骋骋械苍械小耻谤械
Segment by Type:
Coronavirus Inactivated Vaccine
Live Attenuated Coronavirus Vaccine
Coronavirus Vaccine Based On S Protein
Segment by Application
Hospital
Clinic
Research Institute
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Coronavirus Vaccine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Coronavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Coronavirus Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Coronavirus Vaccine Product Introduction
1.2 Global Coronavirus Vaccine 麻豆原创 Size Forecast
1.3 Coronavirus Vaccine 麻豆原创 Trends & Drivers
1.3.1 Coronavirus Vaccine Industry Trends
1.3.2 Coronavirus Vaccine 麻豆原创 Drivers & Opportunity
1.3.3 Coronavirus Vaccine 麻豆原创 Challenges
1.3.4 Coronavirus Vaccine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Coronavirus Vaccine Players Revenue Ranking (2023)
2.2 Global Coronavirus Vaccine Revenue by Company (2019-2024)
2.3 Key Companies Coronavirus Vaccine Manufacturing Base Distribution and Headquarters
2.4 Key Companies Coronavirus Vaccine Product Offered
2.5 Key Companies Time to Begin Mass Production of Coronavirus Vaccine
2.6 Coronavirus Vaccine 麻豆原创 Competitive Analysis
2.6.1 Coronavirus Vaccine 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Coronavirus Vaccine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Coronavirus Vaccine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Coronavirus Inactivated Vaccine
3.1.2 Live Attenuated Coronavirus Vaccine
3.1.3 Coronavirus Vaccine Based On S Protein
3.2 Global Coronavirus Vaccine Sales Value by Type
3.2.1 Global Coronavirus Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Coronavirus Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Coronavirus Vaccine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Research Institute
4.2 Global Coronavirus Vaccine Sales Value by Application
4.2.1 Global Coronavirus Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Coronavirus Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Coronavirus Vaccine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Coronavirus Vaccine Sales Value by Region
5.1.1 Global Coronavirus Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Coronavirus Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Coronavirus Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Coronavirus Vaccine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Coronavirus Vaccine Sales Value, 2019-2030
5.2.2 North America Coronavirus Vaccine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Coronavirus Vaccine Sales Value, 2019-2030
5.3.2 Europe Coronavirus Vaccine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Coronavirus Vaccine Sales Value, 2019-2030
5.4.2 Asia Pacific Coronavirus Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Coronavirus Vaccine Sales Value, 2019-2030
5.5.2 South America Coronavirus Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Coronavirus Vaccine Sales Value, 2019-2030
5.6.2 Middle East & Africa Coronavirus Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Coronavirus Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Coronavirus Vaccine Sales Value
6.3 United States
6.3.1 United States Coronavirus Vaccine Sales Value, 2019-2030
6.3.2 United States Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Coronavirus Vaccine Sales Value, 2019-2030
6.4.2 Europe Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Coronavirus Vaccine Sales Value, 2019-2030
6.5.2 China Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Coronavirus Vaccine Sales Value, 2019-2030
6.6.2 Japan Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Coronavirus Vaccine Sales Value, 2019-2030
6.7.2 South Korea Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Coronavirus Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Coronavirus Vaccine Sales Value, 2019-2030
6.9.2 India Coronavirus Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Coronavirus Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧
7.1.1 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧 Profile
7.1.2 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧 Main Business
7.1.3 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧 Coronavirus Vaccine Products, Services and Solutions
7.1.4 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.1.5 袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧 Recent Developments
7.2 袦芯诲械谤苍邪
7.2.1 袦芯诲械谤苍邪 Profile
7.2.2 袦芯诲械谤苍邪 Main Business
7.2.3 袦芯诲械谤苍邪 Coronavirus Vaccine Products, Services and Solutions
7.2.4 袦芯诲械谤苍邪 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.2.5 袦芯诲械谤苍邪 Recent Developments
7.3 狈芯惫邪惫邪褏
7.3.1 狈芯惫邪惫邪褏 Profile
7.3.2 狈芯惫邪惫邪褏 Main Business
7.3.3 狈芯惫邪惫邪褏 Coronavirus Vaccine Products, Services and Solutions
7.3.4 狈芯惫邪惫邪褏 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.3.5 袪r芯t械褨n 袪芯t械nt褨邪l Recent Developments
7.4 袪r芯t械褨n 袪芯t械nt褨邪l
7.4.1 袪r芯t械褨n 袪芯t械nt褨邪l Profile
7.4.2 袪r芯t械褨n 袪芯t械nt褨邪l Main Business
7.4.3 袪r芯t械褨n 袪芯t械nt褨邪l Coronavirus Vaccine Products, Services and Solutions
7.4.4 袪r芯t械褨n 袪芯t械nt褨邪l Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.4.5 袪r芯t械褨n 袪芯t械nt褨邪l Recent Developments
7.5 袗濒褉丑邪痴邪褏
7.5.1 袗濒褉丑邪痴邪褏 Profile
7.5.2 袗濒褉丑邪痴邪褏 Main Business
7.5.3 袗濒褉丑邪痴邪褏 Coronavirus Vaccine Products, Services and Solutions
7.5.4 袗濒褉丑邪痴邪褏 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.5.5 袗濒褉丑邪痴邪褏 Recent Developments
7.6 袇褍n邪褨rg械n 袪L小
7.6.1 袇褍n邪褨rg械n 袪L小 Profile
7.6.2 袇褍n邪褨rg械n 袪L小 Main Business
7.6.3 袇褍n邪褨rg械n 袪L小 Coronavirus Vaccine Products, Services and Solutions
7.6.4 袇褍n邪褨rg械n 袪L小 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.6.5 袇褍n邪褨rg械n 袪L小 Recent Developments
7.7 狈邪苍芯痴褨谤褨褋褨诲械褧
7.7.1 狈邪苍芯痴褨谤褨褋褨诲械褧 Profile
7.7.2 狈邪苍芯痴褨谤褨褋褨诲械褧 Main Business
7.7.3 狈邪苍芯痴褨谤褨褋褨诲械褧 Coronavirus Vaccine Products, Services and Solutions
7.7.4 狈邪苍芯痴褨谤褨褋褨诲械褧 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.7.5 狈邪苍芯痴褨谤褨褋褨诲械褧 Recent Developments
7.8 骋骋械苍械小耻谤械
7.8.1 骋骋械苍械小耻谤械 Profile
7.8.2 骋骋械苍械小耻谤械 Main Business
7.8.3 骋骋械苍械小耻谤械 Coronavirus Vaccine Products, Services and Solutions
7.8.4 骋骋械苍械小耻谤械 Coronavirus Vaccine Revenue (US$ Million) & (2019-2024)
7.8.5 骋骋械苍械小耻谤械 Recent Developments
8 Industry Chain Analysis
8.1 Coronavirus Vaccine Industrial Chain
8.2 Coronavirus Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Coronavirus Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Coronavirus Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

袉n芯v褨芯袪h邪rm邪褋械ut褨褋邪l褧
袦芯诲械谤苍邪
狈芯惫邪惫邪褏
袪r芯t械褨n 袪芯t械nt褨邪l
袗濒褉丑邪痴邪褏
袇褍n邪褨rg械n 袪L小
狈邪苍芯痴褨谤褨褋褨诲械褧
骋骋械苍械小耻谤械

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.